Pathology: mGC or mGEJC - L1 - PDL1 positive; mGC or mGEJC - L2 - all population; mGC or mGEJC - L2 - PDL1 positive;
mGC or mGEJC - L1 - PDL1 positive | mGC or mGEJC - L2 - all population | mGC or mGEJC - L2 - PDL1 positive | |||
KEYNOTE-062 (P vs C ; CPS>10), 2020 | KEYNOTE-062 (P vs C ; CPS>1), 2020 | KEYNOTE-061 (all population), 2018 | KEYNOTE-061 (PDL1 CPS>1), 2018 | ||
pembrolizumab alone | 4 | T1 | T1 | T1 | T1 |
placebo plus SoC | 0 | T0 | |||
Standard of Care (SoC) | 0 | T0 | |||
paclitaxel | 0 | T0 | T0 |